Items where authors include "Girvan, S."

Article

Slevin, F. orcid.org/0000-0002-7176-904X, Alexander, S., Brown, S.R. orcid.org/0000-0002-7975-7537 et al. (20 more authors) (2024) Pelvis or involved node treatment: eradicating recurrence in prostate cancer (POINTER-PC) – study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open, 14. e095560. ISSN 2044-6055

Slevin, F. orcid.org/0000-0002-7176-904X, Alexander, S., Brown, S.R. orcid.org/0000-0002-7975-7537 et al. (20 more authors) (2024) Pelvis Or Involved Node Treatment: Eradicating Recurrence in Prostate Cancer (POINTER-PC) – study protocol paper for a phase III multicentre, open-label randomised controlled trial. BMJ Open, 14 (12). e095560. ISSN 2044-6055

Munir, T., Cairns, D.A. orcid.org/0000-0002-2338-0179, Bloor, A. et al. (29 more authors) (2023) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine. ISSN 0028-4793

Proceedings Paper

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. In: Blood. 65th ASH: Annual Meeting & Exposition, 09-12 Dec 2023, San Diego, USA. American Society of Hematology , p. 632.